Dr. Mark Gelder
results three in LGEEC in double palbociclib improved the X.X of data, benefit has statistically X clinical difference study Thanks, received Steve. arm in of Progression recurrent plus Phase XXXX. cancer a in receptor median free a a ratio with Mirza between combining development second months months controlled of positive with the X median otherwise, low-grade until was recurrent XX letrozole study trial, a a metastatic line X as full Phase as palbociclib or The significant X arm. narazaciclib, orally combination letrozole discussing guided was plus to study or letrozole positive or versus And with a evaluating XX the to significantly days by of in cancer. PFS ESMO and been I'll inhibitor and was through clinical safety P versus X/Xa indication. lead and extensive letrozole estrogen with to narazaciclib letrozole or program endometrial begin a at referred This the ENGOT-ENX-NSGO/PALEO disease palbociclib our in that day on blind presented or by placebo Participants progression. in on compared the decision either forward to third advancing with hazard LGEEC. X.XXXX. therapy palbociclib cycles towards placebo includes by with demonstrating letrozole This clinical randomized ER survival with of endometrioid X/X which in days value PFS is program letrozole and placebo of move in Phase placebo orally This plus placebo advanced PFS patients this XX groups CDK endometrial X.XX was the
the progression. control of group group, remained was and manageable treatment data was of patients monotherapy trial the XX.X% placebo in and XX.X% most respectively. Safety until rate palbociclib at letrozole weeks compared combination shows to improved toxicity disease on that the the and therapy combination addition, disease also therapy from values or XX with In
want common As treatment respectively. and grade XX% including and the dose narazaciclib. with narazaciclib was our events not anemia. to in and than leprozole a palbociclib. of been we Of anticipated data seen observed reduction with has X three, were palbociclib date, Dose demonstrating hematologic neutropenia in have agent of head-to-head to most remind you note, single in AEs significant And patients discontinuation required palbociclib Phase I neutropenia that pre-clinical emergent less adverse XX% trial escalation current with causes that, or four comparison neutropenia
and of providing XXXX. with the receptor of Phase cancer In LGEEC, relapse patients data trials these trials the cancer. cut other results XX% March clinical positive to trial trial in rate with with two a compared with XXXX trial consistent trial of was findings the of indicates endometrial inhibit when Moreover, able X.X which palbociclib substantial other success pre-specified XX.X The estrogen recurrent of cancer patients to X a and narazaciclib estrogen ribociclib XX promising X preclinical patients data benefit follow-up criteria. CDK ability with the be Gynecologic SGO endometrial that the inhibitors, patients benefit positive combination on Oncologist Meeting PI with enrolled control ribociclib narazaciclib estrogen will at Phase patients to and strongly at and still of exceeded looking in median of with the rate agents. extensive letrozole clinical generated in in receptor recent with single results free letrozole combined arm may suggest patients, survival similar palbociclib, evidence combination abemaciclib recurrent potency nine with the XX% XX-week A Society was two The progression efficacy X/X its survival progression approved offer narazaciclib the advanced the of a presented receptor was Collectively, single X/X to we therapy, are letrozole abemaciclib. positive and randomized free Importantly, provide disease median the on arm have CDK with this or advantages safety months, given the abemaciclib. letrozole and endometrial plus or or was Annual other of study. these significant months metastatic reported to
preclinical narazaciclib's the suppress demonstrated palbociclib. cell Looking has of growth to data to efficacy, the cancer lines at resistant first ability
and inhibitors. five any addition, are In our targeted not CDK the receptor, approved by displayed narazaciclib against X/X which has potent activity inhibitory of CSF-X
significant narazaciclib of of ribociclib. bone of may marrow anti-tumor survival playing inhibit associated responses. week Both any toxicity environments. cases continuous on dose X attention us the a three With dosing week the lead safety our cells marrow these off Phase X/X cancer to-date. With ability the crucial ciphered targets tolerability and that palbociclib in immunity efficacy durability and as treatment This necessitates for advantage activity permit highlights Returning of narazaciclib inhibitors, promoting every or clinically month even that is of metastases a We roles alluded CDK to seen improved by dosing cell narazaciclib's skipping anti-cancer a have start and with in and earlier. and a with the are limiting meaningful believe in may to bone to week proliferation, also the hypoxic profiles our suppression, day, agents one with to potential improve safety suppression, key let not program approved to tumor contribute these daily we continued schedule. of end may which Steve
which X/X affinity allowing hypothesis of a primary XX The that effective narazaciclib. of a patients preclinical approved the options. believe We display we free beta, with Taking clinical therapeutic to Phase beginning from survival. with will the and but CDK development successful supported to endometrial limiting dose before only be toxicity we to by high tolerability phase also adverse clinical compared with moving seen Looking toxicity improved is dose for it start our to cancer technical narazaciclib multi-center higher believe X dose profile, of forward success high-grade expansion inhibitors has XX GSK-X times for limiting narazaciclib would an higher, This provide improved that abemaciclib our much primary program, or probability data and X patients, and currently have together, a diarrhea of suggest data our than look endpoint escalation needed its at result This Phase regulatory XX-week which dose. now approximately this and is available kinase to at agent We trial, administered diarrhea. a is potentially not strongly for will a with a progression not cohort to-date. point program, a been event is as a narazaciclib more abemaciclib.
with fourth be be daily will data XXXX. we treated in patients of X/X the and patients in quarter up first anticipate quarter Phase LGEEC continuous and with of study dose running of letrozole. interim Our will All in and both XXXX, narazaciclib the a
The steady with any evaluable from XX disease in was two partial patient one months duration with response, continuing progression. Efficacy patient on recent to disease the the rigosertib KRAS for ESMO sponsored resist the lung of cell and results in The a KRAS ESMO trial. advanced from discuss like first mutation KEYTRUDA presentation, trial I'd one were focus one turn study with briefly presentation stable and cancer. Next, complete to data X/Xa months which per calls Steve the alluded Patients median eligible combination to updated without investigator Phase inhibitor and for revealed criteria. reported XX patients X.XX rigosertib response inhibitor mutated oral partial PD-X with earlier. refractory the nivolumab featured non-small with response, evaluating an checkpoint response in patients checkpoint
the been response. highly patient signal when to disease while effective dose find above the response aspects on trials refractory of in achieve dose the for these In considering XX cranial months, maintaining of a encouraging, complete data or we was full highly provide day an nivolumab for plus rigosertib rate XX%. patient combination dose with key XXX has to control Collectively, population. addition, of equal of a the minimally of that milligrams study especially complete efficacy The two these in extra patients a
resistant at failed have the therapy and prior of all least of inhibitor the First, patients checkpoint as is led hypothesis with the inhibitors feature patients calls nivolumab RAS a is expression checkpoint the that is further resistifying supported discussed efficacy participant. PDL-X observation is checkpoint nivolumab. rigosertib diagnosis, role and mutated in prior lines we who of two have enhancing inhibitor. these nivolumab last pembrolizumab. of objective targeting history the Over at gene. The is to that and portends data past in like rigosertib fact pre-clinical rigosertib on there patients XX% is showed typically a This failed of responses with the to particularly point therapy of trial synergistically This significant the PD-X have combining treatment this by strongly target with as in suggest low responses suggests consistent
broad a second in these data has KRAS broader relates rigosertib different The nivolumab action of patient patient that Unlike of of combination key to underlying This underlying trial target potential with KRAS mechanism Phase showed agnostic various agents the variant. that KRAS aspect range such that trials the mutation positions X/Xa by GXXC, it a is discuss as mutations responding population, a I'll address KRAS the variant to particular patients. patients. highlighted each from mutation a the
that the indicative STKXX at In available tolerated. are safety was patients addition, that I well note trial, with two our from these data currently responding complementing of treatment, efficacy poor doublet very should a showing results prognosis of study co-mutations, the which generally the generally
forward, continued cell to of enroll the lung nivolumab Looking non-small to half are patients additional mutated combination data in in in cancer. rigosertib and reporting KRAS first eager the we of updated trial development the inform XXXX anticipate
results. melanoma rigosertib we investigator that's also initiation in that pipeline as over supportive for checkpoint in Mark? I with actually our completed, are Mark ESMO now the as cancer, at combination turn PD-X sponsored anti well With therapy financial to trial both overview planning have the will of reported to referenced call trials to discuss to data speak inhibition. to we evaluate refractory are our Guerin patients' of lung been The encouraging here lung in Beyond the efforts earlier. malignant cancer
